We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genomic Analysis Platform Offers Insights into Health, Disease

By Biotechdaily staff writers
Posted on 14 May 2008
An ultra-high throughput genomic analysis system using new technology for DNA sequencing and genomic analysis has enabled scientists to adopt new approaches for studying the genetic basis of health and disease.

The new platform, the SOLiD system is an end-to-end genomic analysis solution utilizing a proprietary technology called stepwise ligation, which generates high quality data for applications including whole genome sequencing, chromatin immunoprecipitation (ChIP), microbial sequencing, digital karyotyping, medical sequencing, genotyping, gene expression, and small RNA discovery.

Applied Biosystems (Warrington, UK) has developed significant new enhancements to the SOLiD system platform, including upgrades to software and chemistry that double throughput, simplify workflows, and decrease system run times.

With the new upgrades, the SOLiD system can consistently generate more than six billion bases of sequence data per run, maintaining the system as the highest throughput genomic analysis system available today. More...
It can also generate up to 240 million sequence tags per run, which is expected to reduce the cost of conducting sequencing-based gene expression applications further.

Scientists at the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard (Cambridge, MA, USA) are using two SOLiD systems for large-scale discovery of genetic variation in human genome samples, as part of the Broad Institute's contribution to the 1000 Genomes Project, a worldwide effort to create the most detailed and medically useful picture of human genetic variation to date. The scientists generated more than 50 billion bases of DNA sequence over just six weeks.

At Columbia University Medical Center (CUMC; New York, NY, USA), scientists have been using the SOLiD system for a novel approach to study whole-genome methylation profiles in a panel of breast cancer tumors, benefiting from the mate-pair analysis capabilities of the system to map the methylation state of all regions of the genome.

The institutes presented their preliminary findings at the Cold Spring Harbor Laboratory's Biology of Genomes meeting in New York (USA) from May 6-10, 2008.


Related Links:
Columbia University Medical Center
Applied Biosystems
Broad Institute of MIT and Harvard

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.